These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 32476587

  • 1. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
    Anderson BE, Luczak TS, Ries LM, Hoefs GE, Silva-Benedict AC.
    J Oncol Pharm Pract; 2020 Dec; 26(8):2028-2030. PubMed ID: 32476587
    [Abstract] [Full Text] [Related]

  • 2. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
    [Abstract] [Full Text] [Related]

  • 3. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
    Paik J, Dhillon S.
    Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
    [Abstract] [Full Text] [Related]

  • 4. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y.
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A, Peled N, Maimon Rabinovich N, Mishaeli M, Shochat T, Zer A, Rotem O, Allen AM, Bar J, Dudnik E, On behalf of the Israel Lung Cancer Group.
    Oncol Res Treat; 2019 Oct; 42(5):275-282. PubMed ID: 30955009
    [Abstract] [Full Text] [Related]

  • 6. Alectinib for advanced ALK-positive non-small-cell lung cancer.
    Ly AC, Olin JL, Smith MB.
    Am J Health Syst Pharm; 2018 Apr 15; 75(8):515-522. PubMed ID: 29467147
    [Abstract] [Full Text] [Related]

  • 7. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K, Naruse I, Shimizu K, Asao T.
    J Cancer Res Ther; 2020 Apr 15; 16(4):919-921. PubMed ID: 32930141
    [Abstract] [Full Text] [Related]

  • 8. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators.
    N Engl J Med; 2017 Aug 31; 377(9):829-838. PubMed ID: 28586279
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
    Ou SH, Weitz M, Jalas JR, Kelly DF, Wong V, Azada MC, Quines O, Klempner SJ.
    Lung Cancer; 2016 Jun 31; 96():15-8. PubMed ID: 27133743
    [Abstract] [Full Text] [Related]

  • 11. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
    Ikeda S, Yoshioka H, Arita M, Sakai T, Sone N, Nishiyama A, Niwa T, Hotta M, Tanaka T, Ishida T.
    Jpn J Clin Oncol; 2015 Feb 31; 45(2):221-4. PubMed ID: 25398579
    [Abstract] [Full Text] [Related]

  • 12. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
    Fukano R, Mori T, Sekimizu M, Choi I, Kada A, Saito AM, Asada R, Takeuchi K, Terauchi T, Tateishi U, Horibe K, Nagai H.
    Cancer Sci; 2020 Dec 31; 111(12):4540-4547. PubMed ID: 33010107
    [Abstract] [Full Text] [Related]

  • 13. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
    Li H, Lai L, Wu B.
    Clin Drug Investig; 2020 Feb 31; 40(2):183-189. PubMed ID: 31820329
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
    Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L.
    Lancet Respir Med; 2019 May 31; 7(5):437-446. PubMed ID: 30981696
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.